Compare Axogen Inc (AXGN) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Cigna Corp — how do they compare? Axogen Inc trades at $48.56 (market cap $2.61B), while Cigna Corp trades at $273.6 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 28.2× Axogen Inc's market cap, and Cigna Corp pays a 2.24% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | CI | |
|---|---|---|
Market Cap | $2.61B | $73.56B |
Sector | Technology | Health |
52-Week High | $48.48 | $311.00 |
52-Week Low | $14.16 | $244.41 |
Enterprise Value | $2.52B | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
Cigna (CI) trades at $278.40, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.51 and ROE of 15.49%. Recent Q2 2026 earnings beat expectations at $7.78 per share, and the company raised its full-year EPS guidance. The stock is supported by consistent dividend payments and robust cash flow from operations of $9.60 billion in 2025.
The outlook is positive with a consensus price target of $338.90, implying 22% upside. Key opportunities include steady earnings growth and capital returns, while risks involve healthcare cost pressures and competitive dynamics. Analyst sentiment is strongly bullish with 73.68% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
